Cited by 320Advanced Glycation End Products researchAdipokines, Inflammation, and Metabolic DiseasesSirtuins and Resveratrol in Medicine

Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes

Open access
Uribarri, Jaime, Cai, Weijing, Ramdas, Maya, Goodman, Susan, Pyzik, Renata, Chen, Xue, Zhu, Li, Striker, Gary E. +1 more·2011·Diabetes Care

Abstract

OBJECTIVE: Increased oxidative stress (OS) and impaired anti-OS defenses are important in the development and persistence of insulin resistance (IR). Several anti-inflammatory and cell-protective mechanisms, including advanced glycation end product (AGE) receptor-1 (AGER1) and sirtuin (silent mating-type information regulation 2 homolog) 1 (SIRT1) are suppressed in diabetes. Because basal OS in type 2 diabetic patients is influenced by the consumption of AGEs, we examined whether AGE consumption also affects IR and whether AGER1 and SIRT1 are involved. RESEARCH DESIGN AND METHODS: The study randomly assigned 36 subjects, 18 type 2 diabetic patients (age 61 ± 4 years) and 18 healthy subjects (age 67 ± 1.4 years), to a standard diet (>20 AGE equivalents [Eq]/day) or an isocaloric AGE-restricted diet (<10 AGE Eq/day) for 4 months. Circulating metabolic and inflammatory markers were assessed. Expression and activities of AGER1 and SIRT1 were examined in patients’ peripheral blood mononuclear cells (PMNC) and in AGE-stimulated, AGER1-transduced (AGER1+), or AGER1-silenced human monocyte-like THP-1 cells. RESULTS: Insulin and homeostasis model assessment, leptin, tumor necrosis factor-α and nuclear factor-κB p65 acetylation, serum AGEs, and 8-isoprostanes decreased in AGE-restricted type 2 diabetic patients, whereas PMNC AGER1 and SIRT1 mRNA, and protein levels normalized and adiponectin markedly increased. AGEs suppressed AGER1, SIRT-1, and NAD+ levels in THP-1 cells. These effects were inhibited in AGER1+ but were enhanced in AGER1-silenced cells. CONCLUSIONS: Food-derived pro-oxidant AGEs may contribute to IR in clinical type 2 diabetes and suppress protective mechanisms, AGER1 and SIRT1. AGE restriction may preserve native defenses and insulin sensitivity by maintaining lower basal OS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-0091

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 26 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Uribarri, J., Cai, W., Ramdas, M., Goodman, S., Pyzik, R., Chen, X., Zhu, L., Striker, G. E., & Vlassara, H.
Affiliations
Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Vlassara, Helen
Venue
Diabetes Care
Published
2011-06-17
Volume
34
Issue
7
Pages
1610-1616
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2061906058
Cited by
320
References
26
Citations by year
2026: 2 · 2025: 14 · 2024: 19 · 2023: 20 · 2022: 24 · 2021: 25 · 2020: 25 · 2019: 16 · 2018: 26 · 2017: 30 · 2016: 26 · 2015: 32 · 2014: 10 · 2013: 31 · 2012: 13
FWCI
11.59
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (R37AG023188, R01AG009453)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK091231)
  • National Center for Research Resources (M01RR000071)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
advanced glycation end products, insulin resistance, type 2 diabetes, SIRT1, oxidative stress, inflammation, NAD+, adiponectin, TNF-α, NF-κB p65 acetylation, 8-isoprostane, peripheral blood mononuclear cells, THP-1 cells
MeSH terms
Receptor for Advanced Glycation End Products, Aged, Cells, Cultured, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Inflammation, Insulin Resistance, Leukocytes, Mononuclear, Male, Middle Aged, Receptors, Immunologic, Glycation End Products, Advanced, Oxidative Stress, Sirtuin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review